Investors don't buy Lyell's solid tumour Car-T success
The ROR1 data are sketchy, and lung toxicity clouds prospects.
The ROR1 data are sketchy, and lung toxicity clouds prospects.
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.